LOVELAND, CO, September 30, 2010 (Press-News.org) Eczema Free Forever TM provides answers to practical, homemade and natural solutions, that the eczema suffering population in any part of the world can easily perform in the comfort of their home.
One in eight people suffer from eczema in the U.S. That's 15 million people. What causes eczema? Which eczema treatment works best? These are questions that the millions of people with the condition ask regularly.
There certainly is no shortage of medicines available on the market that lay claim to being the absolute best cure for eczema. The creams and oily goop that pass for eczema treatments may help soothe the itch for a short while, but watch out because it does come back. When it does, it is usually worse than it originally was.
There is a natural remedy taught by Eczema Free Forever TM that is an at-home treatment proving to be a great eczema cure for the symptoms. So far, the treatments cure eczema symptoms permanently if continued. You will find many reviews from people who have used the product and report total satisfaction. The company is so confident in the positive results that they even offer a 60-day money back guarantee.
The main benefits of the eczema guide can be summarized as follows:
- Eliminate the need for medication
- Stop using harmful creams and gels
- Focus on the root cause of the problem rather than just treating the symptoms
- Learn the causes of eczema and ways by which to eliminate them
- Eliminate dry skin and stop the itching
Eczema Free Forever is a 100% safe and natural home based method with no medication involved. The user of this product will learn how the right diet can help you get rid of eczema and bring a natural, healthy glow to your skin. You may be allergic to food groups you are not aware of them, the guide will teach you detect them and how to handle the changes.
www.fasteczemacure.com
Guide to Natural Eczema Treatments Hits the Market - From Eczema Free Forever TM
Eczema Free Forever TM provides answers to practical, homemade and natural solutions, that the eczema suffering population in any part of the world can easily perform in the comfort of their home.
2010-09-30
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Triple-negative breast cancers may have unique therapeutic target
2010-09-29
DENVER — Patients with triple-negative breast cancer, one of the hardest subtypes to treat, may have a unique biomarker that would enable them to receive more targeted therapy, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Triple-negative breast cancers are breast cancers that have tested negative for estrogen receptors, progesterone receptors and HER2. Because of this biology, these cancers do not respond to endocrine therapies or trastuzumab.
"In other subsets of breast cancer, ...
Circulating tumor cells can provide 'real-time' information on patient's current disease state
2010-09-29
DENVER — Circulating tumor cells (CTCs) may be a promising alternative, noninvasive source of tumor materials for biomarker assessment, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
"The basic idea is that CTCs can provide real-time information about a patient's current disease state, acting as a 'liquid biopsy,'" said Siminder Kaur Atwal, Ph.D., senior research associate at Genentech. "They are much less invasive than tumor biopsies because they can be detected from a blood draw and ...
Biomarker panel identifies prostate cancer with 90 percent accuracy
2010-09-29
DENVER — Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy. This preliminary data, if validated in larger ongoing studies, could be developed into a serum protein test that reduces the number of unnecessary biopsies and identifies men who need treatment before symptoms begin.
The researchers, from Oxford Gene Technology (OGT) and its subsidiary, Sense Proteomic, Ltd., presented their findings at the Fourth AACR International Conference on Molecular ...
New biomarkers discovered for pancreatic cancer and mesothelioma
2010-09-29
DENVER — Using a novel aptamer-based proteomics array technology, researchers and collaborators have identified biomarkers and protein signatures that are hallmarks of cancer at an early stage for two of the most aggressive and deadly forms of cancer — pancreatic and mesothelioma.
This technology would enable better clinical diagnosis at an earlier stage and may provide insight into new therapeutic targets, said Rachel Ostroff, Ph.D., clinical research director of Somalogic Inc.
"Currently these cancers are detected at an advanced stage, where the possibility of cure ...
African-Americans equally likely to benefit from erlotinib and other targeted lung cancer therapy
2010-09-29
DENVER — African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.
"This study has immediate implications for patient management. Patients with EGFR mutations have a much better prognosis and respond better to erlotinib than those who do not," said Ramsi Haddad, Ph.D., director of the Laboratory of Translational Oncogenomics at the Barbara Ann Karmanos Cancer Institute, and assistant ...
Novel biomarker may predict response to new VEGF receptor inhibitor
2010-09-29
DENVER — Researchers believe there may be a way to predict, based on individual tumors, those patients that are more likely to respond to the investigational new drug tivozanib.
This is possible, the researchers from AVEO Pharmaceuticals, Inc. said, because they have used a new way of creating animal tumor models that mimic tumor variation seen in human. Based on the results of these studies, they have found a single biomarker that may predict resistance to tivozanib, an oral, triple VEGF (vascular endothelial growth factor) receptor inhibitor.
Tivozanib is in an ...
Nanotechnology brings personalized therapy 1 step closer to reality
2010-09-29
DENVER — A novel technology can make nanoscale protein measurements, which scientists can use in clinical trials to learn how drugs work.
"We are making progress toward the goal of understanding how drugs work in different individuals," said Alice C. Fan, M.D., instructor in the division of oncology at Stanford University School of Medicine. "Using new technologies makes it possible to measure effects of therapeutic agents in tumor cells and different cell populations within our patients. Now that we can make these measurements, we are one step closer to being able to ...
Method to detect bladder cancer earlier is under development
2010-09-29
DENVER — Scientists may have discovered a way to diagnose bladder cancer at its earliest and, therefore, most treatable stages by measuring the presence or absence of microRNA using already available laboratory tests.
"Measuring expressions of microRNA in bodily fluid represents a very promising tool with widespread implications for screening," said Liana Adam, M.D., Ph.D., assistant professor in urology at The University of Texas MD Anderson Cancer Center.
Adam presented her findings at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic ...
c-Met may be a biomarker for metastatic hepatocellular carcinoma
2010-09-29
DENVER — Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
HCC is the most common primary malignant tumor of the liver; c-Met is a receptor for hepatocyte growth factor that appears to drive liver cancer growth, invasion and metastasis.
"Current therapies for HCC patients are 'one size fits all.' We propose ...
Cost-effectiveness of routine use of pooled nucleic acid amplification testing
2010-09-29
Detection of acute HIV infection (the stage of disease immediately after HIV acquisition but before HIV antibodies are detectable) with pooled nucleic acid amplification testing (that detects the presence of HIV genetic material in the blood before antibodies are detectable) is feasible but not cost-effective in all settings. Rather, pooled nucleic acid amplification testing after testing for antibodies with third-generation enzyme immunoassays (which can detect the first antibody to appear after infection) or rapid testing is only cost-effective when targeted to settings ...
LAST 30 PRESS RELEASES:
Conservation leaders challenge global economic systems that value ‘dead’ nature over living planet
A multidimensional diagnostic approach for COPD
Wearable sensor could be used to monitor OSA treatment response
Waitlist deaths dropped under new lung transplant allocation system
Methotrexate as effective as prednisone in pulmonary sarcoidosis
Waist-to-height ratio predicts heart failure incidence
Climate change increases severity of obstructive sleep apnea
USC, UCLA team up for the world’s first-in-human bladder transplant
Two out of five patients with heart failure do not see a cardiologist even once a year and these patients are more likely to die
AI-enabled ECG algorithm performs well in the early detection of heart failure in Kenya
No cardiac safety concerns reported with a pharmaceutically manufactured cannabidiol formulation
Scientists wash away mystery behind why foams are leakier than expected
TIFRH researchers uncover a mechanism enabling glasses to self-regulate their brittleness
High energy proton accelerator on a table-top — enabled by university class lasers
Life, death and mowing – study reveals Britain’s poetic obsession with the humble lawnmower
Ochsner Transplant Institute’s kidney program achieves ELITE Status
Gender differences in primary care physician earnings and outcomes under Medicare Advantage value-based payment
Can mindfulness combat anxiety?
Could personality tests help make bipolar disorder treatment more precise?
Largest genomic study of veterans with metastatic prostate cancer reveals critical insights for precision medicine
UCF’s ‘bridge doctor’ combines imaging, neural network to efficiently evaluate concrete bridges’ safety
Scientists discover key gene impacts liver energy storage, affecting metabolic disease risk
Study finds that individual layers of synthetic materials can collaborate for greater impact
Researchers find elevated levels of mercury in Colorado mountain wetlands
Study reveals healing the ozone hole helps the Southern Ocean take up carbon
Ultra-robust hydrogels with adhesive properties developed using bamboo cellulose-based carbon nanomaterials
New discovery about how acetaminophen works could improve understanding about pain relievers
What genetic changes made us uniquely human? -- The human intelligence evolved from proximal cis-regulatory saltations
How do bio-based amendments address low nutrient use efficiency and crop yield challenges?
Predicting e-bus battery performance in cold climates: a breakthrough in sustainable transit
[Press-News.org] Guide to Natural Eczema Treatments Hits the Market - From Eczema Free Forever TMEczema Free Forever TM provides answers to practical, homemade and natural solutions, that the eczema suffering population in any part of the world can easily perform in the comfort of their home.